tbuckley/cabot-search huggingface dataset:
Abstract 14035: Parathyroid Hormone and Subclinical Cerebrovascular Disease: Findings From the Atherosclerosis Risk in Communities (ARIC) Brain MRI Study
Authors: Erin D Michos, Di Zhao, Eliseo Guallar, Pamela L Lutsey, Alvaro Alonso, A. R Sharrett, Wendy S Post, Jared P Reis, Thomas H Mosley, Rebecca F Gottesman
Journal: Circulation (2015)

Background: Elevated parathyroid hormone (PTH) levels have been associated with incident hypertension, insulin resistance, endothelial dysfunction, and increased cardiovascular disease events. We hypothesized that elevated PTH would also be associated with subclinical cerebrovascular disease. White matter hyperintensities (WMH) and subclinical infarcts measured on brain MRI are associated with reduced cognitive performance. We examined the relationship of elevated PTH levels with cerebrovascular pathology among white and black participants aged 55-72 in the ARIC Brain MRI study. Methods: We measured PTH from stored serum at visit 3 (1993-1994) among participants free of prior clinical stroke who underwent a brain MRI at visit 3 (n=1703) and a second brain MRI ~10 years later (n=948). PTH levels ≥65 pg/ml were considered elevated (n=204). Participants who did not return for a follow-up MRI had higher PTH levels and increased prevalence of cardiovascular risk factors at visit 3 (p&lt;0.05 for all); therefore multiple imputation methods were used. The cross-sectional and prospective associations of PTH levels with WMH and MRI defined infarcts (and their progression) were investigated using multivariable regression models. Results: At visit 3, mean age of participants was 62 yrs, 60% female and 49% black. In models adjusted for demographic/lifestyle factors, elevated PTH was cross-sectionally associated with higher WMH score and prevalent infarcts ( Table ). Results were attenuated after adjustment for potential cardiovascular risk factor mediators. However, no prospective associations were found between PTH and incident infarcts or change in estimated WMH volume, although estimates were imprecise. Conclusions: Contrary to our hypothesis, we did not confirm any associations of elevated PTH with progression of cerebrovascular changes on serial brain MRIs ~10 years apart. The relationship of PTH with subclinical brain disease warrants further study.
Abstract 17798: Thirty-Day Readmissions After Transcatheter Aortic Valve Replacement in the United States: Insights From the Nationwide Readmissions Database
Authors: Dhaval Kolte, Sahil Khera, Muhammad Rizwan Sardar, Neil Gheewala, Tanush Gupta, Saurav Chatterjee, Andrew Goldsweig, Wilbert S Aronow, Gregg C Fonarow, Deepak L Bhatt, Adam B Greenbaum, Paul C Gordon, Barry L Sharaf, Jinnette D Abbott
Journal: Circulation (2016)

Introduction: Unplanned hospitalizations after cardiac procedures occur frequently and contribute to increased healthcare utilization and costs. Data on 30-day readmissions after transcatheter aort...
Preparation and in vitro-in vivo evaluation of intestinal retention pellets of Berberine chloride to enhance hypoglycemic and lipid-lowing efficacy
Authors: Guofei Li, Mingming Zhao, Xianying Su, Lin Song, Limei Zhao
Journal: Asian Journal of Pharmaceutical Sciences (2018)

Berberine chloride (BBR) is a pharmacokinetic profile of drug with poor bioavailability but good therapeutic efficacy, which is closely related to the discovery of BBR intestinal target. The major aim of this paper is to develop BBR intestinal retention type sustained-release pellets and evaluate their in vivo and in vitro behaviors base on the aspect of local action on intestinal tract. Here, wet milling technology is used to improve dissolution and dissolution rate of BBR by decreasing the particle size and increasing the wettability. The pellets are prepared by liquid layer deposition technology, and then the core pellets are coated with Eudragit® L30D-55 and Eudragit® NE30D aqueous dispersion. The prepared pellets show high drug loading capacity, and the drug loading up to 93%. Meanwhile, it possesses significant sustained drug release effect in purified water which is expected to improve the pharmacokinetic behavior of BBR. The pharmacokinetics results demonstrate that the half-life of BBR was increased significantly from 24 h to 36 h and the inter- and intra-subject variability are decreased compared to commercial BBR tablets. The retention test results indicate that the pellet size and Eudragit® NE30D plays an important role in retention time of the pellet, and it is found that the pellets with small particle size and high Eudragit® NE30D coating content can stay longer in the intestine than the pellets with large particle size. All in all, BBR intestinal retention type pellets are prepared successfully in this study, and the pellets show satisfactory in vivo and in vitro behaviors.
Abstract 16016: Role For Macitentan in Angiogenesis of Right Ventricle, Peripheral Muscle and Lungs in Pulmonary Arterial Hypertension
Authors: Valerie Nadeau, Sebastien Bonnet, Renée Paradis, Eve Tremblay, Francois Potus, Caroline Lambert, Marc Iglarz, Steeve Provencher
Journal: Circulation (2015)

Background: Pulmonary arterial hypertension (PAH) is a vascular disease characterized by remodeling of distal pulmonary arteries (PA) leading to increased mean PA pressure, subsequent right ventricular (RV) failure and ultimately death of patients. Impaired angiogenesis is now recognized as a major factor in PAH etiology. It contributes not only to the decrease in lung perfusion but also to a rarefaction of the capillary network within the skeletal muscle and RV leading to exercise intolerance and RV failure. Several studies have suggested that endothelin-1 (ET-1) contributes to decrease angiogenesis in PAH. In light of these observations, we hypothesized that macitentan, an ET-1 receptors blocker, improves PAH by promoting angiogenesis in lungs, RV and skeletal muscles. Methods/Results: In the Sugen/hypoxia rat model of PAH, we demonstrated by right catheterization in closed chest rats that compared to vehicle treated animals, daily treatment during two weeks with macitentan (30 mg/kg) decreases significantly mean PA pressure (n=8-20; p&lt;0.01) and total pulmonary resistance (n=8-20; p&lt;0.05) and improves cardiac output, stroke volume (n=7-17; p&lt;0.05) and RV hypertrophy measured by echo (n=6-10; p&lt;0.05). These effects were associated with an increase of 2.9 fold in lung blood perfusion (n=6), 4.1 fold in quadriceps perfusion (n=5-7) and 1.5 fold in right ventricle perfusion (n=5-6) measured in vivo by micro CT angiogram (p&lt;0.05). Both in vivo lectin perfusion (n=4-10; p&lt;0.05) and immunologic CD31 staining (n=4-5; p&lt;0.05) confirmed these findings. In the lungs, the hemodynamic and perfusion improvements were associated with decreased vascular remodeling (H&amp;E) (n=6-17; p&lt;0.01). In vitro, using primary cultured human endothelial cells isolated from distal PA (PAEC) and RV (RVEC), we showed that macitentan decreases PAH-PAEC proliferation (Ki67 assay) and resistance to apoptosis (TUNEL assay), while increasing angiogenesis capacity of healthy PAEC and RVEC (matrigel assay). Conclusion: Our data provide structural and functional evidence that ET-1 receptor inhibition with macitentan may improve PAH by promoting angiogenesis.
P2.13-03 Real-Life Experience with Brigatinib in Pretreated EML4-ALK Translocated NSCLC Patients
Authors: M. Hochmair, J. Naber, S. Schwab, U. Setinek, D. Krenbek, M. Holzer, H. Fabikan, S. Watzka, R. Koger, A. Fazekas, E. Bitterlich, A. Valipour, O. Burghuber
Journal: Journal of Thoracic Oncology (2018)
MA21.09 Differential Gene Expression in Tumor and Normal Tissue Reveals New Insights in the Biology of Non-Small Cell Lung Carcinoma.
Authors: A. Spatz, V. Lazar, E. Rubin, K. Lach, H. Wang, A. Papadakis, R. Moscona, P. Jimenez, G. Kasymjanova, V. Cohen, J. Agulnik, L. Kempen
Journal: Journal of Thoracic Oncology (2018)
Survival benefit of adjuvant chemotherapy vs active surveillance in locally advanced nasopharyngeal carcinoma: A multicenter retrospective study
Authors: P. Danchaivijitr, A. Dechaphunkul, C. Paoin, J. Setakornnukul, T. Dechaphunkul, R. Jiratrachu, S. Niyomnaitham, B. Suktitipat, C. Sookthon, P. Pattaranutaporn, C. Jiarpinitnun, N. Ngamphaiboon
Journal: Annals of Oncology (2018)
A phase II study of nab-paclitaxel and gemcitabine in Korean patients with metastatic pancreatic cancer
Authors: S.J. Lee, D.-Y. Oh, J.-H. Kang, H.J. Choi, M.A. Lee, S.Y. Oh, S.-T. Kim, Y.S. Park, B.-Y. Ryu, J.O. Park
Journal: Annals of Oncology (2018)
P2.01-80 Performance Status and Resource Utilization in Patients Receiving Palliaitve Care with Stage IV Non-Small Cell Lung Cancer
Authors: J. Rayburn, C. Wilshire, C. Gilbert, R. Weerasinghe, B. Louie, R. Aye, A. Farivar, E. Vallieres, J. Gorden
Journal: Journal of Thoracic Oncology (2018)
MA21.01 Cbl Mutations (mt) as Important Mediators of Oncogenic RTK Signaling in NSCLC
Authors: R. Feldman, A. Vanderwalde, S. Liu, M. Dietrich, S. Gadgeel, W. Korn, J. Nieva, A. Spira, E. Kim
Journal: Journal of Thoracic Oncology (2018)
Assessment of local clinical practice for testing of mismatch repair deficiency in metastatic colorectal cancer: The need for new diagnostic guidelines prior to immunotherapy
Authors: R. Cohen, E. Hain, O. Buhard, A. Guilloux, A. Bardier, R. Kaci, P. Bertheau, F. Renaud, F. Bibeau, J.-F. Fléjou, T. André, M. Svrcek, A. Duval
Journal: Annals of Oncology (2018)
Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA)
Authors: D.V.T. Catenacci, H. Park, H.E. Uronis, Y.-K. Kang, M. Ng, P. Gold, J. Lacy, P.C. Enzinger, S. Park, K.-W. Lee, J. Yen, J. Odegaard, A. Franovic, J. Baughman, J. Muth, A. Wynter-Horton, T. Wu, J. Wigginton, J.K. Davidson-Moncada, Y.-J. Bang
Journal: Annals of Oncology (2018)
Safety, tolerability, and pharmacokinetics of the OX40 agonist ABBV-368 in patients with advanced solid tumors
Authors: A. Spira, K. Chung, A. Patnaik, A.W. Tolcher, M.E. Blaney, A. Parikh, A. Reddy, W. Henner, M. McDevitt, D. Afar, J. Powderly
Journal: Annals of Oncology (2018)
P3.08-07 An Institution Review of Outcomes of Lung Stereotactic Body Radiotherapy in Various Oligometastatic Disease States
Authors: B. Chia, W.L. Ng, S.P. Yap, K. Chua, C. Yip, A. Thiagarajan, T.R. Siow, K.W. Fong
Journal: Journal of Thoracic Oncology (2018)
Identification and prospective stability of electronic nose (eNose)–derived inflammatory phenotypes in patients with severe asthma
Authors: Paul Brinkman, Ariane H. Wagener, Pieter-Paul Hekking, Aruna T. Bansal, Anke-Hilse Maitland-van der Zee, Yuanyue Wang, Hans Weda, Hugo H. Knobel, Teunis J. Vink, Nicholas J. Rattray, Arnaldo D'Amico, Giorgio Pennazza, Marco Santonico, Diane Lefaudeux, Bertrand De Meulder, Charles Auffray, Per S. Bakke, Massimo Caruso, Pascal Chanez, Kian F. Chung, Julie Corfield, Sven-Erik Dahlén, Ratko Djukanovic, Thomas Geiser, Ildiko Horvath, Nobert Krug, Jacek Musial, Kai Sun, John H. Riley, Dominic E. Shaw, Thomas Sandström, Ana R. Sousa, Paolo Montuschi, Stephen J. Fowler, Peter J. Sterk
Journal: Journal of Allergy and Clinical Immunology (2018)
Overdiagnosis of Penicillin Allergy Leads to Costly, Inappropriate Treatment
Authors: Rita Rubin
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Magnitude of clinical benefit in trials supporting US Food and Drug Administration (FDA) accelerated approval (AA) and European Medicines Agency (EMA) conditional marketing authorisation (CMA) and subsequent trials supporting conversion to full approval
Authors: M. Borrell Puy, C. Molto Valiente, K. Vokinger, T. Hwang, A. Ocana Fernandez, A.J. Templeton, B. Seruga, I. Gich Saladich, A. Barnadas, E. Amir, A. Tibau
Journal: Annals of Oncology (2018)
MA12.05 Phase 1 Study of HSP90 Inhibitor Ganetespib with Pemetrexed and Cisplatin/Carboplatin Chemotherapy for Pleural Mesothelioma
Authors: D. Fennell, S. Danson, M. Forster, D. Talbot, P. Woll, J. Child, Y. Ngai, L. Farrelly, A. Hackshaw, A. Sharkey, S. Busacca, R. Hastings, D. Barnes, M. Nicolson, P. Taylor, S. Ahmed, G. Wheeler
Journal: Journal of Thoracic Oncology (2018)
Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) who received prior chemotherapy (CT) for advanced disease: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial
Authors: F. Cardoso, K. Papazisis, M. De Laurentiis, A. Ring, J. Lu, M. Martín, H.A. Azim, C. Zamagni, K. Zhou, J. Wu, J.P. Zarate, P.H. Cottu
Journal: Annals of Oncology (2018)
P2.17-10 Daily Low–Dose Cisplatin and High Dose Radiotherapy for Elderly Patients with Stage III NSCLC is Well Tolerated.
Authors: E.m.t. Dieleman, R. Van Os, W. Kolff, C.c.e. Koning, J.t. Annema, C.r.n. Rasch
Journal: Journal of Thoracic Oncology (2018)
Relationship between ethnicity and overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S): Results from a Canadian multi-centre HCC database
Authors: D.E. Meyers, R. Lee-Ying, M. Alghamdi, H.-W. Sim, V.O. Zaborska, Y.-J. Ko, T. Raycraft, E. Batuyong, W.Y. Cheung, H. Samawi, J.M. Davies, V.C. Tam
Journal: Annals of Oncology (2018)
Emerging Genetic Therapy for Sickle Cell Disease
Authors: Stuart H. Orkin, Daniel E. Bauer
Journal: Annual Review of Medicine (2018)

The genetic basis of sickle cell disease (SCD) was elucidated >60 years ago, yet current therapy does not rely on this knowledge. Recent advances raise prospects for improved, and perhaps curative, treatment. First, transcription factors, BCL11A and LRF/ZBTB7A, that mediate silencing of the β-like fetal (γ-) globin gene after birth have been identified and demonstrated to act at the γ-globin promoters, precisely at recognition sequences disrupted in rare individuals with hereditary persistence of fetal hemoglobin. Second, transformative advances in gene editing and progress in lentiviral gene therapy provide diverse opportunities for genetic strategies to cure SCD. Approaches include hematopoietic gene therapy by globin gene addition, gene editing to correct the SCD mutation, and genetic manipulations to enhance fetal hemoglobin production, a potent modifier of the clinical phenotype. Clinical trials may soon identify efficacious and safe genetic approaches to the ultimate goal of cure for SCD.
Differential expression of secreted factors <i> <scp>SOSTDC</scp> 1 </i> and <i> <scp>ADAMTS</scp> 8 </i> cause profibrotic changes in linear morphoea fibroblasts
Authors: I.I. Badshah, S. Brown, L. Weibel, A. Rose, B. Way, N. Sebire, G. Inman, J. Harper, R.F.L. O'Shaughnessy
Journal: British Journal of Dermatology (2018)

Linear morphoea (LM) is a rare connective tissue disorder characterized by a line of thickened skin and subcutaneous tissue and can also affect the underlying muscle and bone. Little is known about the disease aetiology, with treatment currently limited to immune suppression, and disease recurrence post-treatment is common.
Phase I study of BVAC-C in HPV type 16 or 18 positive recurrent cervical carcinoma: Safety, clinical activity and immunologic correlates
Authors: C.H. Choi, H.J. Choi, J.-W. Lee, E.-S. Kang, D. Cho, Y.-M. Kim, D. Kim, H. Seo, M. Park, W. Kim, T. Oh, C.-Y. Kang, B.-G. Kim
Journal: Annals of Oncology (2018)
The results of treatment of non-small cell lung cancer stage III with a preoperative vinorelbine/carboplatin and personalized adjuvant chemotherapy
Authors: E.O. Rodionov, S.V. Miller, S.A. Tuzikov, M.M. Tsyganov, N.V. Litviakov, L.A. Efteev, I.V. Deriusheva
Journal: Annals of Oncology (2018)
Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU
Authors: Mette Krag, Søren Marker, Anders Perner, Jørn Wetterslev, Matt P. Wise, Joerg C. Schefold, Frederik Keus, Anne B. Guttormsen, Stepani Bendel, Mark Borthwick, Theis Lange, Bodil S. Rasmussen, Martin Siegemund, Helle Bundgaard, Thomas Elkmann, Jacob V. Jensen, Rune D. Nielsen, Lisbeth Liboriussen, Morten H. Bestle, Jeanie M. Elkjær, Dorte F. Palmqvist, Minna Bäcklund, Jon H. Laake, Per M. Bådstøløkken, Juha Grönlund, Olena Breum, Akil Walli, Robert Winding, Susanne Iversen, Inge-Lise Jarnvig, Jonathan O. White, Björn Brand, Martin B. Madsen, Lars Quist, Klaus J. Thornberg, Anders Møller, Jørgen Wiis, Anders Granholm, Carl T. Anthon, Tine S. Meyhoff, Peter B. Hjortrup, Søren R. Aagaard, Jo B. Andreasen, Christina A. Sørensen, Pernille Haure, Jacob Hauge, Alexa Hollinger, Jonas Scheuzger, Daniel Tuchscherer, Thierry Vuilliomenet, Jukka Takala, Stephan M. Jakob, Marianne L. Vang, Kim B. Pælestik, Karen L.D. Andersen, Iwan C.C. van der Horst, Willem Dieperink, Jesper Fjølner, Cilia K.W. Kjer, Christine Sølling, Christoffer G. Sølling, Johanna Karttunen, Matt P.G. Morgan, Brit Sjøbø, Janus Engstrøm, Birgit Agerholm-Larsen, Morten H. Møller
Journal: New England Journal of Medicine (2018)

Prophylaxis for gastrointestinal stress ulceration is frequently given to patients in the intensive care unit (ICU), but its risks and benefits are unclear.In this European, multicenter, parallel-group, blinded trial, we randomly assigned adults who had been admitted to the ICU for an acute condition (i.e., an unplanned admission) and who were at risk for gastrointestinal bleeding to receive 40 mg of intravenous pantoprazole (a proton-pump inhibitor) or placebo daily during the ICU stay. The primary outcome was death by 90 days after randomization.A total of 3298 patients were enrolled; 1645 were randomly assigned to the pantoprazole group and 1653 to the placebo group. Data on the primary outcome were available for 3282 patients (99.5%). At 90 days, 510 patients (31.1%) in the pantoprazole group and 499 (30.4%) in the placebo group had died (relative risk, 1.02; 95% confidence interval [CI], 0.91 to 1.13; P=0.76). During the ICU stay, at least one clinically important event (a composite of clinically important gastrointestinal bleeding, pneumonia, Clostridium difficile infection, or myocardial ischemia) had occurred in 21.9% of patients assigned to pantoprazole and 22.6% of those assigned to placebo (relative risk, 0.96; 95% CI, 0.83 to 1.11). In the pantoprazole group, 2.5% of patients had clinically important gastrointestinal bleeding, as compared with 4.2% in the placebo group. The number of patients with infections or serious adverse reactions and the percentage of days alive without life support within 90 days were similar in the two groups.Among adult patients in the ICU who were at risk for gastrointestinal bleeding, mortality at 90 days and the number of clinically important events were similar in those assigned to pantoprazole and those assigned to placebo. (Funded by Innovation Fund Denmark and others; SUP-ICU ClinicalTrials.gov number, NCT02467621 .).
P1.04-01 Impact of Chromatin Remodeling Genes Including SMARCA2 and PBRM1 on Neoantigen and Immune Landscape of NSCLC
Authors: L.C. Park, S. Chang, T. Ko, K. Rhee, J. Anker, M. Bhave, A. Davis, M. Cruz, W. Iams, L. Zou, V. Wang, J. Chuang, Y. Chae
Journal: Journal of Thoracic Oncology (2018)
Judge lambasts UK as “agent of harm” in cases of young people with serious mental health problems
Authors: Clare Dyer
Journal: BMJ (2018)

A High Court judge has delivered a scathing attack on UK authorities’ failure to provide enough secure therapeutic placements for children and teenagers with serious mental health problems, accusing the state of having become an “agent of harm.”

Mr Justice Hayden was delivering judgment in the “truly shocking” case of a girl, “D,” who he said had been “subjected to profound physical and emotional harm” during a five month wait for a placement to allow her needs to be met.

D, whose age was not disclosed, has autism and learning difficulties and had absconded from her parents’ home. She was being cared for at Alder Hey Children’s Hospital, where four security guards were placed around the clock …
Oregovomab (orego) and nivolumab (nivo) as a combinatorial immunotherapy strategy for recurrent epithelial ovarian cancer (rEOC): ORION-01 phase Ib cohort
Authors: J.J. Chan, S.H. Tan, T.W. Lim, T.J.Y. Tan, W.Y. Chay, E.H. Lim, L.T. Soh, S.L. Lim, J.W.K. Chia
Journal: Annals of Oncology (2018)
OA03.03 Phase 2B of Blueprint PD-L1 Immunohistochemistry Assay Comparability Study
Authors: K. Kerr, M. Tsao, Y. Yatabe, E. Thunnissen, A. Nicholson, A. Moreira, T. Chou, A. Borczuk, L. Bubendorf, M. Mino-Kenudson, J. Botling, M.B. Beasley, L. Chirieac, S. Dacic, S. Lantuejoul, G. Pelosi, J. Chung, G. Chen, P. Russell, C. Poleri, J. Sauter, H. Yu, M. Noguchi, I. Wistuba, M. Pintilie, M. Wynes, F. Hirsch
Journal: Journal of Thoracic Oncology (2018)
A multi-institutional randomized phase II study on the timing of oxaliplatin plus 5-fluorouracil (FOLFOX) for patients (pts) with operable stage III rectal cancer: The KIR study
Authors: P. Kavan, I. Barrera, L. Azoulay, A.-G. Martin, C. Vasilevsky, M. Boutros, E. Ferland, G. Batist, T. Vuong
Journal: Annals of Oncology (2018)
Unmet needs in the management of neuroendocrine tumours (NETs): A global survey of patients, patient advocates and healthcare professionals
Authors: C.V. Bouvier, M. Caplin, S. Conroy, P. Davies, S. Dureja, M. Falconi, P. Ferolla, G.A. Fisher, G. Goldstein, R.J. Hicks, R. Hollander, T. Kolarova, B. Lawrence, S. Leyden, Y. Majima, D. Metz, D. O’Toole, P. Ruszniewski, B. Wiedenmann
Journal: Annals of Oncology (2018)
Cell-free circulating tumour DNA (ctDNA) in the management of patients with non-biopsiable advanced non-small cell lung cancer (NSCLC)
Authors: M. Kushnir, H. Winter, C. Murias, P. Bains, C.Z. Abbosh, D. Papadatos-Pastos, T. Newsome-Davis, T. Ahmed, C. Swanton, M.D. Forster, D. Moore, P. Bennett, I. Faull, R.B. Lanman, H.-T. Arkenau
Journal: Annals of Oncology (2018)
Acceptability in cancer outpatients of completing routine assessments of patient reported outcomes of common terminology criteria for adverse events (PRO-CTCAE) versus other patient reported symptom outcome tools
Authors: H. Albaba, M.C. Brown, S. Shakik, S. Su, H. Naik, T. Wang, M. Liang, A. Perez-Cosio, L. Eng, N. Mittmann, W. Xu, G. Liu, D. Howell, T.A. Barnes
Journal: Annals of Oncology (2018)
Implications of thymidylate synthase gene polymorphisms, KRAS and BRAF mutations in the survival of patients with colorectal cancer treated with adjuvant chemotherapy
Authors: A. Ntavatzikos, A. Spathis, P. Patapis, G. Peros, I. Panayiotides, I. Papadopoulos, A. Koumarianou
Journal: Annals of Oncology (2018)
Responder analysis based on patient-reported outcomes (PROs) and clinical endpoints (CEPs) in patients (pts) with metastatic Merkel cell carcinoma (mMCC) treated with avelumab
Authors: S.P. D'Angelo, F. Fofana, M. Schlichting, M. Henry-Szatkowski, M. Hennessy, M. Bharmal
Journal: Annals of Oncology (2018)